On September 21, 2020, the exercise period ends for Saniona's warrants of series TO 2, which can strengthen the company by approximately SEK 37 million before issue costs. Holders of TO 2 have the right to subscribe for one new share in Saniona for each warrant at a price of SEK 25 per share. BioStock reached out to Saniona's CEO Rami Levin, who has made steady progress building the Saniona team and advancing Tesomet and other potential treatments for rare diseases.